Heloisa Soares examined the unmet need in managing neuroendocrine tumors (NETs), the impact of current phase 3 trials on the management of well-differentiated NETs, the role of molecular profiling in neuroendocrine neoplasm management, and how future guidelines for gastroenteropancreatic NETs may change with the recent theranostics developments.

Maribel del Olmo reviewed the advantages and disadvantages of somatostatin analogs for patients with somatostatin receptor-positive neuroendocrine tumors, the evolving treatment landscape for these patients, the necessary steps if a non-functional NET becomes functional during radiopharmaceutical therapy, and the promising advancements in innovative radiopharmaceuticals.

This webcast is from the satellite symposium titled “HOW TO SPEAK ‘THERANOSTICS’ IN NET: Translating Key Principles into Clinical Practice” that took place at the European Neuroendocrine Tumor Society (ENETS) Annual Congress on 6^th March 2025 in Krakow, Poland.